KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Shares Issued (2016 - 2025)

Vertex Pharmaceuticals has reported Shares Issued over the past 17 years, most recently at $54.0 million for Q4 2025.

  • Quarterly results put Shares Issued at $54.0 million for Q4 2025, up 57.43% from a year ago — trailing twelve months through Dec 2025 was $127.7 million (up 11.43% YoY), and the annual figure for FY2025 was $127.7 million, up 11.43%.
  • Shares Issued for Q4 2025 was $54.0 million at Vertex Pharmaceuticals, up from $7.9 million in the prior quarter.
  • Over the last five years, Shares Issued for VRTX hit a ceiling of $64.4 million in Q2 2022 and a floor of $7.9 million in Q3 2025.
  • Median Shares Issued over the past 5 years was $34.5 million (2021), compared with a mean of $33.3 million.
  • Biggest five-year swings in Shares Issued: crashed 80.4% in 2021 and later surged 165.22% in 2022.
  • Vertex Pharmaceuticals' Shares Issued stood at $34.7 million in 2021, then skyrocketed by 48.7% to $51.6 million in 2022, then decreased by 10.08% to $46.4 million in 2023, then dropped by 26.08% to $34.3 million in 2024, then soared by 57.43% to $54.0 million in 2025.
  • The last three reported values for Shares Issued were $54.0 million (Q4 2025), $7.9 million (Q3 2025), and $49.1 million (Q2 2025) per Business Quant data.